NYSE American - Delayed Quote USD

Impact BioMedical Inc. (IBO)

Compare

1.7690

+0.1990

+(12.68%)

At close: January 24 at 3:59:53 PM EST

1.7000

-0.07

(-3.90%)

After hours: January 24 at 6:56:32 PM EST

Impact BioMedical Inc. to Present at The Microcap Conference

HOUSTON, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chief Executive Officer, is pleased to announce his participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atl

GlobeNewswire 3 days ago

IBO
+12.68%
Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision

HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chairman and Chief Executive Officer of Impact BioMedical Inc., issued the following letter to Impact BioMedical shareholders regarding recent achievements, executional efficiencies and the positive outlook for the Company’s future. Dear Impact Biomedic

GlobeNewswire 2 months ago

IBO
+12.68%
PRPH
Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease

HOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE: IBO), is thrilled to announce a significant milestone in its innovative Linebacker™ technology platform. The Canadian Intellectual Property Office has issued Canadian Patent #3,024,728 entitled “Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders". This patent includes claims to novel enhanced phenolic compounds and pharmaceutical compositions as well as their uses in treat

GlobeNewswire 3 months ago

IBO
+12.68%
Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates

HOUSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, is pleased to announce the successful completion of its Initial Public Offering (IPO). Notable is that over 30% of the IPO was purchased by existing investors which further demonstrates strong belief in the company and its potential. Frank D. Heuszel, CEO of Impact BioMedical, commented, "Th

GlobeNewswire 3 months ago

IBO
+12.68%
Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue

HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (“IBO”) is pleased to announce that the US Patent and Trademark Office has issued U.S. Patent No. 11,985,973 entitled “Insect Repelling Composition” developed within IBO’s 3F™ technology platform. This is in addition to IBO’s prior granted U.S. Patent No. 11,246,310. Both patents include compositions and formulations of constituents found in plants and fragrances produced by plants, which, when applied as a natural insect repelle

GlobeNewswire 3 months ago

IBO
+12.68%
Impact BioMedical Inc. Introduces Leadership Team to Drive Innovation and Growth

NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting unique healthcare solutions, is pleased to introduce its executive leadership team, poised to lead the company through its next phase of innovation and growth. “We are excited to introduce our exceptional leadership team, which brings together a wealth of experience and a shared vision for driving innovation and growth at

GlobeNewswire 4 months ago

IBO
+12.68%
Impact BioMedical Inc. Announces the Closing of its Initial Public Offering

NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness, today announced the closing of its previously announced initial public offering of 1,500,000 shares of its common stock at a public offering price of $3.00 per share. The shares began trading on the NYSE American Market on September 16, 2024, under the ticker symbol “IBO”. In addition, Impact has granted the underwriters a

GlobeNewswire 4 months ago

IBO
+12.68%
DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE American: IBO), is delighted to announce the successful pricing of Impact BioMedical's initial public offering (IPO). Impact BioMedical, a trailblazer in advancing human healthcare and wellness solutions, has set its IPO price at $3.00 per share, with an initial offering of 1,500,000 shares. Trading under the ticker symbol “IBO,” these shares will begin

GlobeNewswire 4 months ago

DSS

IBO
+12.68%
Impact BioMedical Inc. Announces Pricing of Initial Public Offering

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness today announced the pricing of its initial public offering of 1,500,000 shares of its common stock at a public offering price of $3.00 per share. The shares are expected to begin trading on the NYSE American Market on September 16, 2024, under the ticker symbol “IBO.” The offering is expected to close on September 17, 2024,

GlobeNewswire 4 months ago

IBO
+12.68%

Performance Overview

Return	IBO	S&P 500
YTD	+17.93%	+3.29%
1-Year	-41.03%	+25.42%
3-Year	-41.03%	+38.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Impact BioMedical Inc. (IBO)

Impact BioMedical Inc. to Present at The Microcap Conference

Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision

Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease

Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates

Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue

Impact BioMedical Inc. Introduces Leadership Team to Drive Innovation and Growth

Impact BioMedical Inc. Announces the Closing of its Initial Public Offering

DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value

Impact BioMedical Inc. Announces Pricing of Initial Public Offering

Performance Overview